Rugo HS - Search Results

1

Strategic Combinations to Prevent and Overcome Resistance to Targeted Therapies in Oncology.

Gumusay O, Vitiello PP, Wabl C, Corcoran RB, Bardelli A, Rugo HS. Gumusay O, et al. Among authors: rugo hs. Am Soc Clin Oncol Educ Book. 2020 May;40:e292-e308. doi: 10.1200/EDBK_280845. Am Soc Clin Oncol Educ Book. 2020. PMID: 32453634 Free article.

2

Challenging clinical scenarios: treatment of patients with triple-negative or basal-like metastatic breast cancer.

Greenberg S, Rugo HS. Greenberg S, et al. Among authors: rugo hs. Clin Breast Cancer. 2010 Sep;10 Suppl 2:S20-9. doi: 10.3816/CBC.2010.s.009. Clin Breast Cancer. 2010. PMID: 20805062 Review.

3

Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer.

Rugo HS, Stopeck AT, Joy AA, Chan S, Verma S, Lluch A, Liau KF, Kim S, Bycott P, Rosbrook B, Bair AH, Soulieres D. Rugo HS, et al. J Clin Oncol. 2011 Jun 20;29(18):2459-65. doi: 10.1200/JCO.2010.31.2975. Epub 2011 May 9. J Clin Oncol. 2011. PMID: 21555686 Clinical Trial.

4

Everolimus and its role in hormone-resistant and trastuzumab-resistant metastatic breast cancer.

Keck S, Glencer AC, Rugo HS. Keck S, et al. Among authors: rugo hs. Future Oncol. 2012 Nov;8(11):1383-96. doi: 10.2217/fon.12.143. Future Oncol. 2012. PMID: 23148612

5

New developments in metastatic breast cancer: integrating recent data into clinical practice.

Perez EA, Rugo HS, Vahdat LT. Perez EA, et al. Among authors: rugo hs. Clin Adv Hematol Oncol. 2013;11(10 Suppl 16):1-18; quiz 19. Clin Adv Hematol Oncol. 2013. PMID: 24892840

6

Dosing and Safety Implications for Oncologists When Administering Everolimus to Patients With Hormone Receptor-Positive Breast Cancer.

Rugo HS. Rugo HS. Clin Breast Cancer. 2016 Feb;16(1):18-22. doi: 10.1016/j.clbc.2015.09.004. Epub 2015 Sep 29. Clin Breast Cancer. 2016. PMID: 26507507 Free article. Review.

7

Improving Response to Hormone Therapy in Breast Cancer: New Targets, New Therapeutic Options.

Rugo HS, Vidula N, Ma C. Rugo HS, et al. Am Soc Clin Oncol Educ Book. 2016;35:e40-54. doi: 10.1200/EDBK_159198. Am Soc Clin Oncol Educ Book. 2016. PMID: 27249746 Free article. Review.

8

Highlights in breast cancer from the 2017 American Society of Clinical Oncology Annual Meeting.

Rugo HS. Rugo HS. Clin Adv Hematol Oncol. 2017 Aug;15(8):607-614. Clin Adv Hematol Oncol. 2017. PMID: 28949948 No abstract available.

9

Emerging data on improving response to hormone therapy: the role of novel targeted agents.

Vidula N, Rugo HS. Vidula N, et al. Among authors: rugo hs. Expert Rev Anticancer Ther. 2018 Jan;18(1):3-18. doi: 10.1080/14737140.2018.1412259. Epub 2017 Dec 8. Expert Rev Anticancer Ther. 2018. PMID: 29192520 Review.

10

Methylome Variation Predicts Exemestane Resistance in Advanced ER⁺ Breast Cancer.

Liu XR, Zhang RY, Gong H, Rugo HS, Chen LB, Fu Y, Che JW, Tie J, Shao B, Wan FL, Kong WY, Song GH, Jiang HF, Xu GB, Li HP. Liu XR, et al. Among authors: rugo hs. Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033819896331. doi: 10.1177/1533033819896331. Technol Cancer Res Treat. 2020. PMID: 32129154 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

529 results

Search Page

Filters